Cardiac Marker Testing Market Size, Share, Trends, Growth Outlook

Cardiac Marker Testing Market is estimated to increase at a Compounded Annual Growth Rate of 10.5% CAGR over the forecast period from 2024 to 2030

The Cardiac Marker Testing Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Product (Reagents and Kits, Instruments), By Biomarker (Troponin I and T, Creatine kinase-MB(CK-MB), Brain Natriuretic peptide, Myoglobin, High-sensitivity C-reactive protein, Others), By Disease (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, Ischemia), By End-User (Laboratory Testing Facilities, Point-Of-Care Testing Facilities, Academic Institutions).

An Introduction to Cardiac Marker Testing Market in 2024

Cardiac marker testing involves the measurement of specific proteins and enzymes released into the bloodstream in response to myocardial injury or stress, aiding in the diagnosis and risk stratification of cardiovascular conditions. In 2024, cardiac marker tests include biomarkers such as troponin, creatine kinase-MB (CK-MB), and brain natriuretic peptide (BNP), which are used to detect acute myocardial infarction, heart failure, and other cardiac events. These tests provide valuable information about cardiac function, ischemia, and damage, helping clinicians assess the severity of myocardial injury, guide treatment decisions, and monitor patient progress over time. With advancements in assay sensitivity, point-of-care testing, and high-sensitivity troponin assays, cardiac marker testing offers rapid and accurate diagnostic capabilities, enabling timely interventions and improved outcomes for patients with acute and chronic cardiovascular conditions. As the burden of cardiovascular disease continues to rise globally, cardiac marker testing remains a cornerstone of cardiovascular care, supporting early detection, risk stratification, and optimal management of patients with heart disease.

Market Trend: Shift Towards High-Sensitivity Cardiac Marker Assays

One prominent trend in the cardiac marker testing market is the shift towards high-sensitivity cardiac marker assays. High-sensitivity assays offer improved sensitivity and precision in detecting cardiac biomarkers such as troponin, creatine kinase-MB (CK-MB), and natriuretic peptides, allowing for the early and accurate diagnosis of acute myocardial infarction (heart attack), heart failure, and other cardiovascular conditions. With growing emphasis on early intervention and risk stratification in cardiovascular disease management, high-sensitivity cardiac marker testing has become increasingly important in clinical practice. Healthcare providers are adopting these advanced assays to enhance diagnostic accuracy, optimize patient outcomes, and streamline decision-making in the management of cardiac patients. Furthermore, high-sensitivity cardiac marker assays enable the identification of individuals at higher risk of adverse cardiovascular events, facilitating targeted interventions and personalized treatment strategies, thereby driving the adoption of high-sensitivity cardiac marker testing in healthcare settings worldwide.

Market Driver: Rising Burden of Cardiovascular Diseases and Acute Cardiac Events

A significant driver in the cardiac marker testing market is the rising burden of cardiovascular diseases and acute cardiac events. Cardiovascular diseases, including coronary artery disease, myocardial infarction, and heart failure, are leading causes of morbidity and mortality globally, posing significant healthcare challenges and economic burdens on healthcare systems. Timely and accurate diagnosis of acute cardiac events is critical for initiating appropriate treatment and preventing complications, such as irreversible myocardial damage, heart failure, and death. Cardiac marker testing plays a pivotal role in the diagnostic pathway for acute cardiac events by detecting myocardial injury and providing valuable information on the extent and severity of cardiac damage. With the increasing prevalence of cardiovascular risk factors such as hypertension, diabetes, obesity, and sedentary lifestyles, the demand for cardiac marker testing continues to grow, driven by the need for early detection, risk stratification, and effective management of cardiovascular diseases and acute cardiac events.

Market Opportunity: Integration of Cardiac Marker Testing into Point-of-Care (POC) Settings

An emerging opportunity in the cardiac marker testing market is the integration of cardiac marker testing into point-of-care (POC) settings. Point-of-care testing offers several advantages, including rapid turnaround time, convenience, and accessibility, enabling timely decision-making and treatment initiation at the patient's bedside, emergency department, or outpatient clinic. The integration of cardiac marker testing into POC platforms allows for immediate assessment of cardiac biomarkers, facilitating early diagnosis of acute myocardial infarction and rapid triage of patients with suspected cardiac chest pain. Moreover, POC cardiac marker testing enables healthcare providers to monitor cardiac biomarker levels serially during hospitalization or ambulatory care, guiding treatment decisions and assessing response to therapy in real-time. By expanding the availability of cardiac marker testing to POC settings, healthcare systems can improve patient outcomes, reduce healthcare costs associated with unnecessary hospital admissions and diagnostic delays, and enhance the efficiency of cardiovascular care delivery. The integration of cardiac marker testing into POC platforms presents opportunities for innovation and collaboration among diagnostic companies, healthcare providers, and technology developers, driving the development of user-friendly, portable, and cost-effective POC testing solutions for cardiac biomarkers.

Cardiac Marker Testing Market Share Analysis: High-Sensitivity C-reactive Protein (hs-CRP) Testing for Atherosclerosis is the fastest growing segment over the forecast period to 2030

Among the segments in the Cardiac Marker Testing Market, the High-Sensitivity C-reactive Protein (hs-CRP) Testing for Atherosclerosis segment is experiencing the fastest growth. This growth can be attributed to several factors driving the demand for hs-CRP testing in the assessment of atherosclerotic cardiovascular disease (ASCVD) risk. High-sensitivity C-reactive protein is a biomarker of systemic inflammation, and elevated levels of hs-CRP have been strongly associated with increased risk of atherosclerosis, coronary artery disease, and cardiovascular events. As the understanding of the role of inflammation in atherosclerosis pathogenesis has evolved, hs-CRP testing has emerged as a valuable tool for risk stratification and prognostication in individuals at risk of ASCVD. Healthcare providers utilize hs-CRP testing alongside traditional risk factors, such as cholesterol levels and blood pressure, to identify individuals who may benefit from more aggressive preventive interventions, such as statin therapy or lifestyle modifications. Additionally, hs-CRP testing plays a crucial role in monitoring the response to therapy and guiding treatment decisions in patients with established cardiovascular disease. The availability of rapid and reliable hs-CRP testing assays, including automated chemiluminescence and immunoturbidimetric methods, has facilitated its integration into laboratory and point-of-care testing facilities, expanding access to hs-CRP testing in diverse healthcare settings. With the growing emphasis on personalized medicine and preventive cardiology, coupled with the increasing recognition of inflammation as a key driver of atherosclerosis, the High-Sensitivity C-reactive Protein Testing for Atherosclerosis segment is expected to sustain its rapid growth in the Cardiac Marker Testing Market.

Cardiac Marker Testing Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbott Laboratories, Becton, Dickinson and Company, bioMérieux SA, Bio-Rad Laboratories Inc, Danaher Corp, DiaSorin , F. Hoffmann-La Roche AG, LSI Medience Corp, PerkinElmer Inc, Quidel Corp, Siemens Healthineers AG, Thermo Fisher Scientific Inc, Tosoh Corp

Cardiac Marker Testing Market Segmentation

By Product
Reagents and Kits
Instruments
-Chemiluminescence
-Immunofluorescence
-ELISA
-Immunochromatography
By Biomarker
Troponin I and T
Creatine kinase-MB(CK-MB)
Brain Natriuretic peptide
Myoglobin
High-sensitivity C-reactive protein
Others
By Disease
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Ischemia
By End-User
Laboratory Testing Facilities
Point-Of-Care Testing Facilities
Academic Institutions
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Cardiac Marker Testing Market Companies

Abbott Laboratories
Becton, Dickinson and Company
bioMérieux SA
Bio-Rad Laboratories Inc
Danaher Corp
DiaSorin
F. Hoffmann-La Roche AG
LSI Medience Corp
PerkinElmer Inc
Quidel Corp
Siemens Healthineers AG
Thermo Fisher Scientific Inc
Tosoh Corp

Reasons to Buy the Cardiac Marker Testing Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Cardiac Marker Testing Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Cardiac Marker Testing Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Cardiac Marker Testing Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Cardiac Marker Testing Market Size Outlook, $ Million, 2021 to 2030
3.2 Cardiac Marker Testing Market Outlook by Type, $ Million, 2021 to 2030
3.3 Cardiac Marker Testing Market Outlook by Product, $ Million, 2021 to 2030
3.4 Cardiac Marker Testing Market Outlook by Application, $ Million, 2021 to 2030
3.5 Cardiac Marker Testing Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Cardiac Marker Testing Industry
4.2 Key Market Trends in Cardiac Marker Testing Industry
4.3 Potential Opportunities in Cardiac Marker Testing Industry
4.4 Key Challenges in Cardiac Marker Testing Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Cardiac Marker Testing Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Cardiac Marker Testing Market Outlook by Segments
7.1 Cardiac Marker Testing Market Outlook by Segments, $ Million, 2021- 2030
By Product
Reagents and Kits
Instruments
-Chemiluminescence
-Immunofluorescence
-ELISA
-Immunochromatography
By Biomarker
Troponin I and T
Creatine kinase-MB(CK-MB)
Brain Natriuretic peptide
Myoglobin
High-sensitivity C-reactive protein
Others
By Disease
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Ischemia
By End-User
Laboratory Testing Facilities
Point-Of-Care Testing Facilities
Academic Institutions

8 North America Cardiac Marker Testing Market Analysis and Outlook To 2030
8.1 Introduction to North America Cardiac Marker Testing Markets in 2024
8.2 North America Cardiac Marker Testing Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Cardiac Marker Testing Market size Outlook by Segments, 2021-2030
By Product
Reagents and Kits
Instruments
-Chemiluminescence
-Immunofluorescence
-ELISA
-Immunochromatography
By Biomarker
Troponin I and T
Creatine kinase-MB(CK-MB)
Brain Natriuretic peptide
Myoglobin
High-sensitivity C-reactive protein
Others
By Disease
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Ischemia
By End-User
Laboratory Testing Facilities
Point-Of-Care Testing Facilities
Academic Institutions

9 Europe Cardiac Marker Testing Market Analysis and Outlook To 2030
9.1 Introduction to Europe Cardiac Marker Testing Markets in 2024
9.2 Europe Cardiac Marker Testing Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Cardiac Marker Testing Market Size Outlook by Segments, 2021-2030
By Product
Reagents and Kits
Instruments
-Chemiluminescence
-Immunofluorescence
-ELISA
-Immunochromatography
By Biomarker
Troponin I and T
Creatine kinase-MB(CK-MB)
Brain Natriuretic peptide
Myoglobin
High-sensitivity C-reactive protein
Others
By Disease
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Ischemia
By End-User
Laboratory Testing Facilities
Point-Of-Care Testing Facilities
Academic Institutions

10 Asia Pacific Cardiac Marker Testing Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Cardiac Marker Testing Markets in 2024
10.2 Asia Pacific Cardiac Marker Testing Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Cardiac Marker Testing Market size Outlook by Segments, 2021-2030
By Product
Reagents and Kits
Instruments
-Chemiluminescence
-Immunofluorescence
-ELISA
-Immunochromatography
By Biomarker
Troponin I and T
Creatine kinase-MB(CK-MB)
Brain Natriuretic peptide
Myoglobin
High-sensitivity C-reactive protein
Others
By Disease
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Ischemia
By End-User
Laboratory Testing Facilities
Point-Of-Care Testing Facilities
Academic Institutions

11 South America Cardiac Marker Testing Market Analysis and Outlook To 2030
11.1 Introduction to South America Cardiac Marker Testing Markets in 2024
11.2 South America Cardiac Marker Testing Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Cardiac Marker Testing Market size Outlook by Segments, 2021-2030
By Product
Reagents and Kits
Instruments
-Chemiluminescence
-Immunofluorescence
-ELISA
-Immunochromatography
By Biomarker
Troponin I and T
Creatine kinase-MB(CK-MB)
Brain Natriuretic peptide
Myoglobin
High-sensitivity C-reactive protein
Others
By Disease
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Ischemia
By End-User
Laboratory Testing Facilities
Point-Of-Care Testing Facilities
Academic Institutions
12 Middle East and Africa Cardiac Marker Testing Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Cardiac Marker Testing Markets in 2024
12.2 Middle East and Africa Cardiac Marker Testing Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Cardiac Marker Testing Market size Outlook by Segments, 2021-2030
By Product
Reagents and Kits
Instruments
-Chemiluminescence
-Immunofluorescence
-ELISA
-Immunochromatography
By Biomarker
Troponin I and T
Creatine kinase-MB(CK-MB)
Brain Natriuretic peptide
Myoglobin
High-sensitivity C-reactive protein
Others
By Disease
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Ischemia
By End-User
Laboratory Testing Facilities
Point-Of-Care Testing Facilities
Academic Institutions

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
Becton, Dickinson and Company
bioMérieux SA
Bio-Rad Laboratories Inc
Danaher Corp
DiaSorin
F. Hoffmann-La Roche AG
LSI Medience Corp
PerkinElmer Inc
Quidel Corp
Siemens Healthineers AG
Thermo Fisher Scientific Inc
Tosoh Corp

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Reagents and Kits
Instruments
-Chemiluminescence
-Immunofluorescence
-ELISA
-Immunochromatography
By Biomarker
Troponin I and T
Creatine kinase-MB(CK-MB)
Brain Natriuretic peptide
Myoglobin
High-sensitivity C-reactive protein
Others
By Disease
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Ischemia
By End-User
Laboratory Testing Facilities
Point-Of-Care Testing Facilities
Academic Institutions
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)